SLC26A9 and cancer: Overall, these results suggest that the interactions between S9-A13 and both SLC26A9 and TP53 are stable and reliable, providing strong theoretical and experimental support for the potential of S9-A13 as a precision therapeutic targeting multiple key proteins to regulate cancer stem cell functions and the tumor microenvironment.